Jianxin Medical Shines at China-Hospeq 2024 with Debut of Original Innovations and Full-Stack Solutions
High-quality development in the healthcare sector is undoubtedly the prevailing theme at present.
The 30th China International Medical Equipment Exhibition and Technical Exchange Conference (China-Hospeq 2024), hosted by the International Exchange and Cooperation Center of the National Health Commission, was held at the China National Convention Center in Beijing from August 9 to 11, under the theme “Advancing High-Quality Development in Healthcare.”
As a premier industry event, the conference has attracted more than 200 companies from over ten countries and regions, including China, Germany, the United States, the Netherlands, and Sweden. Exhibitors include multinational giants such as Siemens and GE HealthCare, as well as leading domestic medical device manufacturers like United Imaging.
As a major innovator in the industry,Qingdao Jianxin Medical Technology Co., Ltd. (hereinafter referred to as “Jianxin Medical”) made its debut at the exhibition, showcasing several original innovative products and its “medical device product-level comprehensive solutions.” Located adjacent to Siemens and United Imaging, and directly opposite GE HealthCare, its booth attracted significant industry attention right from the start, with a steady stream of visitors, making it a shining new star at the event.
It is reported that,Qingdao Jianxin Medical presented a comprehensive “Digital Product Realization Pathway and Industrial Ecosystem Development,” showcasing its core strengths in medical device innovation, R&D, production, manufacturing, and supply chain management through three themed exhibits: “Medical Innovation Corridor,” “Original Innovative Products,” and “Processing and Manufacturing Capabilities.”
At the China-Hospeq conference, many experts noted that China is not lacking in innovative products; rather, it lacks innovative products that can guarantee stability and consistency. Achieving consistent product quality requires robust manufacturing capabilities and strong supply chain support.
To this end, Qingdao Jianxin Medical Technology Co., Ltd. has entered into a collaboration with FII Yukang Medical Technology (Shenzhen) Co., Ltd., a subsidiary of Foxconn Industrial Internet Co., Ltd., to establish a “R&D and Manufacturing Center for High-End Medical Devices.”, through a “full-stack” R&D and manufacturing model, we engage in collaborative innovation to provide original “product-grade” solutions to the global market.
At the booth of Qingdao Jianxin Medical Technology Co., Ltd., manufacturing capabilities were showcased as a key exhibition area.It is reported that this also marks the first time Foxconn Yuxiang has participated in China-Hospeq, joining hands with Jianxin Medical to showcase its R&D, manufacturing, and production capabilities.——The products involved on-site include ultrasonic scalpels, staplers, metallic implants, orthopedic instruments, medical plastic components, and more. Qingdao Jianxin Medical Technology Co., Ltd. possesses its own R&D platforms for real-time imaging technology, acoustic-electrical energy technology, ultrasonic therapy technology, and materials and process technology, along with innovative product solutions built upon these foundations. Coupled with the medical device manufacturing capabilities brought by the “High-End Medical Device R&D and Manufacturing Center” established in collaboration with Foxconn Yuxiang, this will undoubtedly provide stronger momentum to the industry.
With a global outlook and a mission to deliver original products, both parties will further leverage their respective strengths in product R&D and design, system integration, performance optimization and validation, raw material development, processing technologies, and manufacturing. Together, they will provide the industry with comprehensive, product-level solutions featuring original innovations, thereby enabling high-quality, high-efficiency R&D and manufacturing of original medical device products.
To develop an original medical device product, it is essential to identify genuine unmet clinical needs.
Jianxin Medical conducted cluster analysis on over 170,000 clinical invention patents, indexing key information such as medical device classification, indications, and technical efficacy by anatomical site and disease. This approach enabled an in-depth analysis of technological development trends and pain points within specific subfields.At the China-Hospeq conference, Qingdao Jianxin Medical Technology Co., Ltd. showcased its original analytical reports in multiple fields—including stomatology, urology, orthopedics, thoracic surgery, and neurosurgery—based on patent cluster analysis. These reports were presented via interactive computer screens within the company’s “Innovation Corridor” exhibit. Taking the stomatology report as an example, it featured not only patent trend analysis and patent layout analysis from a clinical application perspective, but also an analysis of high-incidence diseases, device classifications, and clinical pain points in the field of stomatology. By establishing a patent analysis system centered on clinical pain points, Qingdao Jianxin Medical has built an innovation model that drives product research and development through patent analysis.
Identifying clinical pain points and needs is merely the first step in product development; the successful implementation of product innovation also requires support from a diverse and robust technical team.However, not all startups are able to assemble a multidisciplinary team of technical talent, which often makes it difficult for them to develop innovative products based on genuine clinical needs, even when they have identified real pain points in clinical practice. In contrast, after precisely identifying clinical pain points, Jianxin Medical can rapidly leverage its multidisciplinary R&D team—covering acoustics, optics, electronics, and mechanics—as well as its mastery of original technologies across energy-based devices, imaging, and non-invasive modalities. By collaborating with a consortium of companies, it creates products that truly meet clinical needs with consistent, high-quality standards—includingMultiple Original Innovative Products Showcased On-Site at China-Hospeq, such as:
Dual-Frequency Ultrasonic Lithotripsy System (Under Development), a domestically developed original product, is suitable for the entire urinary lithotripsy system and can simultaneously output ultrasonic frequencies of 25 kHz and 60 kHz. Its originally designed ultrasonic energy conversion and emission device, along with high-strength and high-toughness ultrasonic waveguide rods, can effectively avoid thermal injury during ureteral stone surgery;
Intelligent Dual-Engine Dynamic Hybrid Energy Surgical System (Under Development), successfully approved for the National Key R&D Program Special Project by the Ministry of Science and Technology in November 2022. It has completed registration testing and entered the NMPA’s green channel for approval. The device can intelligently switch between electrical and ultrasonic energy output using the same disposable instrument according to tissue characteristics, enabling “on-demand” adaptability during clinical procedures;
Ultrasonic Soft Tissue Cutting and Hemostasis Device, has obtained the NMPA Class III medical device registration certificate, has been applied in multiple surgical robot systems, and has established technical collaborations with several internationally renowned enterprises.
The aforementioned original products attracted a large number of industry peers at the exhibition to engage in discussions on technical details. The most frequently asked-about product was Jianxin Medical’s flagship “Intelligent Dual-Engine Dynamic Hybrid Energy Surgical System,” whose “adaptive versatility” feature also received praise from overseas attendees. It is reported that, in addition to the multiple original products showcased at the exhibition, Jianxin Medical has several other innovative products currently under development, which are expected to be unveiled to the public in the near future.
To better support the R&D of therapeutic devices tailored for operating room scenarios, Qingdao Jianxin Medical Technology Co., Ltd. has collaborated with Shenzhen Glory Medical Instrument Co., Ltd. and Jiangsu Dongxing Smart Medical Technology Co., Ltd. to establish integrated smart operating rooms, pioneering an “integrated” model for operating room scenario development.Through this model, surgical instrument products can effectively integrate with the operating room spatial integration system via device integration systems, thereby better facilitating the upgrade and iteration of integrated smart operating rooms in healthcare institutions. Meanwhile, leveraging the clinical validation advantages of smart operating rooms, innovative products can also obtain pre-market usability testing and post-market usability evaluation services through research-oriented usability validation laboratories, providing maximum support for the research, development, and market launch of innovative products.
Achieving high-quality development in the medical device industry, progressing from domestic substitution to domestic superiority and even “overtaking on the straightaway,” thereby leading the global medical device sector, is clearly not something a single enterprise can accomplish. It requires collaborative efforts across the entire industry to achieve leapfrog development of China’s medical device sector, ultimately transforming comprehensively from the previous state of low clinical value, poor product quality, and industrial inefficiency to one characterized by high clinical value, superior product quality, and high industrial efficiency.
Jianxin Medical, with technology asset sharing at its core, is also contributing its strength. At China-Hospeq, Jianxin Medical and Qingchuang Huiyi (Qingdao) Technology Co., Ltd. signed an agreement to “jointly build a medical device industry platform.”, striving to support industrial development through the integration and reallocation of diverse resource elements. This is also reflected in the setup of the “Innovation Corridor” at Qingdao Jianxin Medical Technology Co., Ltd.’s exhibition booth.
A digital professional technology sharing platform centered on whole-industry-chain data comprises: an innovation system oriented toward clinical pain points and based on patent cluster analysis; an industrial ecosystem aimed at the precise allocation of supply chain and service chain resources; and a financial ecosystem service framework grounded in post-investment capital empowerment.One way to understand this is that by building the “product engine” of a digital professional technology-sharing platform, it is possible to empower innovative enterprises across the entire chain from R&D to market launch, production, and sales, thereby genuinely reducing operational costs and improving production efficiency. This undoubtedly requires support from superior resources. It is reported that the platform currently aggregates nearly 10,000 professional service institutions, more than 3,000 upstream suppliers in specialized segments, and over 10,000 investment firms, enabling it to provide high-quality, end-to-end services to enterprises.
To drive the development of the entire industry, it is undoubtedly essential for stakeholders across production, academia, research, healthcare, government, capital, and business to join hands in promoting industrial innovation, thereby “earning time-based value” through efficient growth. We also believe that as overall industry efficiency improves and products gain recognition from hospitals, and as medical device manufacturers deepen their collaborative partnerships with upstream suppliers in R&D, production, and manufacturing, we will be closer than ever to achieving the goal of domestic superiority and even “overtaking on the straightaway” in the medical device sector.